Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3797MR)

This product GTTS-WQ3797MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3797MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8255MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ10759MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ5099MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ6713MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ8851MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ8417MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ11906MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ3680MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW